WO2014088520A1 - Utilisation de combinaisons d'extrait de fruit de figuier et d'extrait de feuille d'olivier associées à des extraits de thé vert et de pépins de raisin - Google Patents

Utilisation de combinaisons d'extrait de fruit de figuier et d'extrait de feuille d'olivier associées à des extraits de thé vert et de pépins de raisin Download PDF

Info

Publication number
WO2014088520A1
WO2014088520A1 PCT/TR2013/000287 TR2013000287W WO2014088520A1 WO 2014088520 A1 WO2014088520 A1 WO 2014088520A1 TR 2013000287 W TR2013000287 W TR 2013000287W WO 2014088520 A1 WO2014088520 A1 WO 2014088520A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
green tea
grape seed
olive leaf
fruit
Prior art date
Application number
PCT/TR2013/000287
Other languages
English (en)
Inventor
Mustafa ERASLAN
Original Assignee
Eraslan Mustafa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eraslan Mustafa filed Critical Eraslan Mustafa
Publication of WO2014088520A1 publication Critical patent/WO2014088520A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention is related to a herbal pharmaceutical product prepared in order to be used as a supportive product and supplement for eliminating cancer cells that have been formed and preventing the formation of cancer cells by adding green tea extracts and grape (Vitis) seed extracts to the combination of fig (Ficus carica) and olive (Olea europaea) plant combinations and the present invention is also related to the formulation of said pharmaceutical product.
  • Green tea is a tea obtained from the leaves of Camellia sinensis plant. Although green tea is obtained from the same plant "Camellia Sinensis" as black tea, the only difference between them is the processing technique. The leaves of green tea undergo less process in comparison to black tea. The leaves of the green tea plant do not lose its green colour or its freshness. Black tea is subjected to oxidization whereas green tea is not subjected to oxidization and thus it is protected against the decrease of the antioxidant agents it contains. Both teas have caffeine but the caffeine rate content inside green tea is lower. Both green tea and black tea have antioxidant characteristics but the amount of antioxidant inside green tea is higher as it undergoes less process. This difference gives green tea its specific scent. More importantly it ensures the protection of polyphenols within its structure.
  • Green tea provides protection against various cancer types and heart diseases.
  • EGCG epigallocatechin gallate
  • Green tea is considerably safe as both an extract and as tea. As the extracts did not contain caffeine they are accepted to be safer than tea. Green tea has been used for medical purposes for the past 4000 years in China. It has been used for headaches, body pains, indigestion, depression, a supportive medication for the immune system, toxin removal, and as medication that provides energy and prolongs life. In modern medicine the following characteristics have been observed: The risk of cancer is decreased (by the aid of the catechins inside green tea). Green tea prevents oesophagus cancer in men at the rate of 57% and at the rate of 60% in women. Green tea decreases the risk of prostate cancer by two thirds when it is consumed regularly.
  • Green tea protects against the damage caused by ultraviolet rays that lead to skin cancer. It decreases the size of tumour. It is an antioxidant. The antioxidant inside green tea is 20 times stronger than vitamin E. It lowers cholesterol. It balances blood pressure and blood sugar. It kills bacteria. It kills influenza virus. It prevents mouth odour.
  • Caffeine, flavonoids, polysaccharides, fluoride, vitamin E, EGCG (Epigallocatechin Gallate) is present in green tea.
  • the effect of green tea on its own has been known for years.
  • the grape seed inside the combination is known to be the strongest antioxidant as it contains vitamin e.
  • the grape seed extract shows anti diabetic and antioxidant effects.
  • the effects of grape seed extract on liver damages have been examined by taking into consideration aspartame trans amylase, alanine transferase and glutathione at Ankara University and it has been found out that it protects against many reasons that cause damage such as liver free radical damage.
  • resveratrol which is non flavonoid
  • compositions such as proanthocyanidine and catechinflavonoid
  • vitamins B1,B2,C,E, potassium, phosphor sodium, sulphur, magnesium, tartaric, citric, maleic, succinic, fumaric, gliyseric, glycolic, dimethyl-succinic, and acids such as quinic acids are present inside the grape seed located within the combination.
  • the ficus carica fruit (fig fruit) extract and the olive leaf extract within the combination have each been known to have antioxidant effects that strengthen the immune system for the years.
  • each of the antioxidant effects of the extracts are known and are used. Although using these products separately shows antioxidant effect and although they prevent the development of cancer cells, they need to reach the therapeutic dosage in order to show the same effect. In such a case each product needs to be continually taken in high doses separately.
  • Sweeteners and preservatives are added into a sufficient amount of water and the mixture is heated and cooled. All kinds of sweeteners and artificial sweeteners can be used. Liquid fig fruit extract, olive leaf extract, green tea leaf extract and grape seed extracts are added on top and are mixed. Propyleneglycole and glyserole is added to the mixture and mixed. The mixture is balanced with citric acid with a pH between 5-6. All kinds of Ph adjusters can be used as tampon materials instead of citric acid and the desired volume is completed by adding pure water. The mixture is mixed for some time and is poured into 100 or 200ml glass bottles. Preparation method (rigid gelatine capsule):
  • Solid fig fruit extract, solid olive leaf extract, solid green tea leaf extract and solid grape seed extract within this combination developed for solid and liquid dosage types to be taken orally are obtained in different amounts and magnesium stearate is added and the mixture is mixed until it is homogenous.
  • Other lubricants can be used instead of magnesium stearate.
  • the homogenous mixture is filled into rigid gelatine capsules.
  • the product can be produced in dosage forms such as soft gelatine capsules, tablets, pellets, sachets, or in solid, semi solid or liquid forms such as syrup.
  • the amount of the olive leaf extract added into the mixture, the amounts of fig fruit extracts, green tea leaf extracts and grape seed extract amounts change in accordance with the active agent amounts they comprise. For this reason each extract amount may show a difference in the combination.
  • the 1 unit green tea leaf extract equivalent to fig fruit extract is 0,5-1,5 units
  • the extract carrying oleuropein of olive leaf could be between 1 to 5 units
  • the grape seed extract can be 0,5-2 units, preferably 1 unit within the combination.
  • the rate of the olive leaf extract can vary between 1-5 units in comparison to the rate of the fig fruit extract green tea leaf extract and grape seed extract and is formulated as 3 units preferably.
  • liquid extracts can be used within the combination, solid extracts can also be used.
  • the extract combination developed according to the present invention is used as a supportive and supplementary agent in regulating blood pressure and blood sugar, strengthening the immune system, eliminating cancer cells that have been formed and preventing the formation of new cancer cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un produit pharmaceutique phytothérapeutique préparé dans l'objectif d'être utilisé comme produit de soutien et complément pour éliminer les cellules cancéreuses qui se sont formées et empêcher la formation de cellules cancéreuses, par addition d'extraits de thé vert et d'extraits de pépins de raisin (Vitis) à la combinaison de combinaisons de plantes de figuier (Ficus carica) et d'olivier (Olea europaea), et la présente invention concerne également la formulation dudit produit pharmaceutique.
PCT/TR2013/000287 2012-12-03 2013-09-03 Utilisation de combinaisons d'extrait de fruit de figuier et d'extrait de feuille d'olivier associées à des extraits de thé vert et de pépins de raisin WO2014088520A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2012/13981 2012-12-03
TR201213981 2012-12-03

Publications (1)

Publication Number Publication Date
WO2014088520A1 true WO2014088520A1 (fr) 2014-06-12

Family

ID=49517613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2013/000287 WO2014088520A1 (fr) 2012-12-03 2013-09-03 Utilisation de combinaisons d'extrait de fruit de figuier et d'extrait de feuille d'olivier associées à des extraits de thé vert et de pépins de raisin

Country Status (1)

Country Link
WO (1) WO2014088520A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104491184A (zh) * 2015-01-21 2015-04-08 通化斯威药业股份有限公司 一种能调节血压、降低血脂、软化血管的外用药物及制备方法
WO2016149424A1 (fr) * 2015-03-16 2016-09-22 Nature's Sunshine Products, Inc. Phytocomplexes présentant de multiples activités antioxydantes synergiques, utiles dans des aliments, des compléments alimentaires, des produits cosmétiques et des préparations pharmaceutiques
FR3054441A1 (fr) * 2016-07-28 2018-02-02 Actina Utilisation de metabolites issues de la fermentation de lactobacillus afin de restaurer l'equilibre du microbiote cutane et intestinal
US10702550B1 (en) 2019-09-10 2020-07-07 King Saud University Synthesis of olive leaf extract silver nanoparticles
WO2022257936A1 (fr) * 2021-06-07 2022-12-15 Global Preventive Medicine Biotech Company Limited Procédé et composition pour la prévention et le traitement de la covid-19 et de la covid longue

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033356A2 (fr) * 2005-09-14 2007-03-22 Mitsui Norin Co., Ltd Compositions et procedes de modification d'enzymes de detoxification par des catechines du the vert
US20070071871A1 (en) * 2005-09-28 2007-03-29 Shrikhande Anil J Grape extract, dietary supplement thereof, and processes therefor
US20080254135A1 (en) * 2007-04-10 2008-10-16 Marvin Heuer Resveratrol-containing compositions for general health and vitality
WO2012032494A1 (fr) * 2010-09-10 2012-03-15 Behrooz Kasraee Composition contenant un extrait de matériel végétal de figuier et son utilisation dans le traitement de l'hyperplasie bénigne de la prostate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033356A2 (fr) * 2005-09-14 2007-03-22 Mitsui Norin Co., Ltd Compositions et procedes de modification d'enzymes de detoxification par des catechines du the vert
US20070071871A1 (en) * 2005-09-28 2007-03-29 Shrikhande Anil J Grape extract, dietary supplement thereof, and processes therefor
US20080254135A1 (en) * 2007-04-10 2008-10-16 Marvin Heuer Resveratrol-containing compositions for general health and vitality
WO2012032494A1 (fr) * 2010-09-10 2012-03-15 Behrooz Kasraee Composition contenant un extrait de matériel végétal de figuier et son utilisation dans le traitement de l'hyperplasie bénigne de la prostate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BOUALLAGUI Z ET AL: "Hydroxytyrosol rich extract from olive leaves modulates cell cycle progression in MCF-7 human breast cancer cells", FOOD AND CHEMICAL TOXICOLOGY, PERGAMON, GB, vol. 49, no. 1, 1 January 2011 (2011-01-01), pages 179 - 184, XP027567326, ISSN: 0278-6915, [retrieved on 20101016] *
MCCARTY ET AL: "Targeting multiple signaling pathways as a strategy for managing prostate cancer: Multifocal signal modulation therapy", INTEGRATIVE CANCER THERAPIES, SAGE PUBLICATIONS, THOUSAND OAKS, CA, US, vol. 3, no. 4, 1 January 2004 (2004-01-01), pages 349 - 380, XP009095023, ISSN: 1534-7354, DOI: 10.1177/1534735404270757 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104491184A (zh) * 2015-01-21 2015-04-08 通化斯威药业股份有限公司 一种能调节血压、降低血脂、软化血管的外用药物及制备方法
WO2016149424A1 (fr) * 2015-03-16 2016-09-22 Nature's Sunshine Products, Inc. Phytocomplexes présentant de multiples activités antioxydantes synergiques, utiles dans des aliments, des compléments alimentaires, des produits cosmétiques et des préparations pharmaceutiques
JP2018510217A (ja) * 2015-03-16 2018-04-12 ネイチャーズ サンシャイン プロダクツ、インク． 食品、栄養補助食品、化粧品および医薬品に有用な複数の相乗的抗酸化活性を示すフィトコンプレックス
US10434131B2 (en) 2015-03-16 2019-10-08 Nature's Sunshine Products, Inc. Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations
US11331363B2 (en) 2015-03-16 2022-05-17 Nature's Sunshine Products, Inc. Phytocomplexes exhibiting multiple, synergistic antioxidant activities useful in foods, dietary supplements, cosmetics and pharmaceutical preparations
FR3054441A1 (fr) * 2016-07-28 2018-02-02 Actina Utilisation de metabolites issues de la fermentation de lactobacillus afin de restaurer l'equilibre du microbiote cutane et intestinal
US10702550B1 (en) 2019-09-10 2020-07-07 King Saud University Synthesis of olive leaf extract silver nanoparticles
WO2022257936A1 (fr) * 2021-06-07 2022-12-15 Global Preventive Medicine Biotech Company Limited Procédé et composition pour la prévention et le traitement de la covid-19 et de la covid longue

Similar Documents

Publication Publication Date Title
Vishnoi et al. Green Tea (Camellia sinensis) and its antioxidant property: A review
Siddiqui et al. Antioxidants of the beverage tea in promotion of human health
Kumadoh et al. Dosage forms of herbal medicinal products and their stability considerations-an overview
Gupta et al. A review on the beneficial effects of tea polyphenols on human health
WO2014088520A1 (fr) Utilisation de combinaisons d'extrait de fruit de figuier et d'extrait de feuille d'olivier associées à des extraits de thé vert et de pépins de raisin
WO2016192507A1 (fr) Composition possédant un effet blanchissant et son application
KR20120007275A (ko) 식물혼합추출물을 함유하는 면역증강용 조성물
Pinheiro et al. Nature as a source of drugs for ophthalmology
KR102306737B1 (ko) 큰도꼬마리 어린순 추출물을 함유하는 항산화용 건강식품
JP2022121645A (ja) 更年期症状の予防及び／又は改善組成物
CN106310236A (zh) 一种抗氧化sod口腔喷雾剂及其制备方法
Raghu et al. Neuroprotective effects of dietary plants and phytochemicals against radiation-induced cognitive and behavioral deficits: a comprehensive review of evidence and prospects for future research
KR101412057B1 (ko) 동백나무 추출물을 유효성분으로 함유하는 노화 또는 암 예방 또는 치료용 조성물
CN108367036A (zh) 制备具有提高的脂溶性多酚含量的草本组合物的方法、由此制备的草本组合物及其用途
Younes et al. Sweet Bell Pepper: A Focus on Its Nutritional Qualities and Illness-Alleviated Properties
Marnewick Rooibos and honeybush: recent advances in chemistry, biological activity and pharmacognosy
KR20100026835A (ko) 염증 억제능을 갖는 녹차 산성 다당체 및 이를 함유하는 항염 조성물
KR101736882B1 (ko) 제주조릿대 추출물을 이용한 방사선 방호 또는 면역력 증진용 조성물
EP3341002B1 (fr) Composition à base d'herbes médicinales pour le traitement de maladies maculaires liées à l'âge
Kiliçgün et al. In vitro antioxidant effect of Rosa canina in different antioxidant test systems
CN102499300B (zh) 一种具有抗氧化功效的固体茶及其制备方法
CN109954008A (zh) 一种杀灭幽门螺杆菌治疗胃溃疡的沙棘原花青素软胶囊及制法
Pradhan et al. Beneficial properties of green tea
CN104971161A (zh) 藤茶提取物的痤疮治疗用途
KR102585685B1 (ko) 식물 추출물을 유효성분으로 포함하는 자외선에 의한 피부손상 예방 또는 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13785957

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09/09/2015

122 Ep: pct application non-entry in european phase

Ref document number: 13785957

Country of ref document: EP

Kind code of ref document: A1